Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most ...

The updated stool test for colon cancer finds more cancers and has fewer false positives, meaning fewer people need follow-up ...

Cologuard is getting an upgrade after 10 years on the market, as Exact Sciences starts to roll out the new version of its ...

Exact Sciences has launched its new "Cologuard Plus" test. This test is gaining attention as the most accurate non-invasive ...

Exact Sciences (EXAS) announced the launch of Cologuard Plus, which it calls “the most accurate noninvasive colorectal cancer screening test ...

Learn more about whether Alvotech or Exact Sciences Corporation is a better investment based on AAII's A+ Investor grades, ...

Exact Sciences estimate based on historical patient billing as of November 2024. Exceptions for coverage may apply; only patients’ insurers can confirm how the Cologuard test would be covered.

Corient Private Wealth LLC trimmed its position in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 40.9% during ...

Envestnet Portfolio Solutions Inc. lessened its position in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 10.6% ...